RiboX Therapeutics Reports Positive RXRG001 Trial Results
The FDA has granted the circular RNA treatment Regenerative Medicine Advanced Therapy designation.
Updated on Oct. 22, 2026 in Biotech
Live Poll
Do you trust emerging genetic therapies to effectively treat chronic conditions like dry mouth?
RiboX Therapeutics has announced positive results from a Phase I/II study of its circular RNA treatment, RXRG001, for patients suffering from radiation-induced dry mouth. The FDA has officially granted the therapy Regenerative Medicine Advanced Therapy designation following the study findings.
Why it matters
Radiation therapy for head and neck cancer often causes permanent damage to salivary glands, and this treatment seeks to restore function by improving water transport in surviving cells.
In the low-dose group, unstimulated saliva flow increased by 47%, 300%, and 450% after three months compared to initial levels. Participants received either a 4-µg or 10-µg dose, with no dose-limiting toxicities observed over at least four months of follow-up.
The players
RiboX Therapeutics
This biotechnology company focuses on the development of circular RNA therapies for various medical conditions.
Food and Drug Administration
This federal agency is responsible for protecting public health by regulating pharmaceuticals and medical devices in the United States.
The details
RXRG001 utilizes lipid nanoparticles to deliver circRNA that encodes the aquaporin-1 protein to salivary epithelium cells. During the SPRINX-1 study involving six patients, all treatment-related adverse events were reported as grade 1 or 2.
Timeline
September 2026: The FDA granted Regenerative Medicine Advanced Therapy designation to RXRG001.
October 2026: Study findings for the treatment were published in NEJM.
Mid-2027: The clinical study is expected to reach completion.
The Big Picture
This development follows the guidelines set by the FDA's Regenerative Medicine Advanced Therapy designation program. The FDA's Regenerative Medicine Advanced Therapy designation program is designed to expedite the review of high-potential treatments for unmet medical needs.
This experimental treatment offers a potential future option for patients suffering from persistent dry mouth due to radiation therapy. The therapy is not currently available for general clinical use, as it is still undergoing testing for safety and efficacy.
The takeaway
This study highlights the growing potential of circular RNA platforms to address long-term side effects from cancer treatments. Future updates will focus on the expansion of the participant group and long-term efficacy results.
What happens next
The ongoing SPRINX-1 study is expected to complete its enrollment of 42 patients and finish the clinical trial by the middle of 2027.
Further reading
For additional context on emerging medical technologies, visit the Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust emerging genetic therapies to effectively treat chronic conditions like dry mouth?
